These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

348 related items for PubMed ID: 24289170

  • 1. A benefit-risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathy.
    Walker A, Watson C, Alexopoulos ST, Deniz B, Arnold R, Bates D.
    Curr Med Res Opin; 2014 Apr; 30(4):629-35. PubMed ID: 24289170
    [Abstract] [Full Text] [Related]

  • 2. Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
    Campbell JD, McQueen RB, Miravalle A, Corboy JR, Vollmer TL, Nair K.
    Am J Manag Care; 2013 Apr; 19(4):278-85. PubMed ID: 23725360
    [Abstract] [Full Text] [Related]

  • 3. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.
    N Engl J Med; 2012 May 17; 366(20):1870-80. PubMed ID: 22591293
    [Abstract] [Full Text] [Related]

  • 4. Natalizumab in relapsing-remitting multiple sclerosis.
    Outteryck O.
    Expert Rev Neurother; 2016 May 17; 16(5):471-81. PubMed ID: 27008031
    [Abstract] [Full Text] [Related]

  • 5. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
    Soilu-Hänninen M, Päivärinta M, Sonninen P, Parkkola R, Vuorinen T, Erälinna JP.
    Duodecim; 2013 May 17; 129(7):765-70. PubMed ID: 23720945
    [Abstract] [Full Text] [Related]

  • 6. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
    N'gbo N'gbo Ikazabo R, Mostosi C, Quivron B, Delberghe X, El Hafsi K, Lysandropoulos AP.
    Clin Ther; 2016 Mar 17; 38(3):670-5. PubMed ID: 26856928
    [Abstract] [Full Text] [Related]

  • 7. Quantitative risk-benefit analysis of natalizumab.
    Thompson JP, Noyes K, Dorsey ER, Schwid SR, Holloway RG.
    Neurology; 2008 Jul 29; 71(5):357-64. PubMed ID: 18663181
    [Abstract] [Full Text] [Related]

  • 8. Progressive multifocal leukoencephalopathy and natalizumab.
    Hellwig K, Gold R.
    J Neurol; 2011 Nov 29; 258(11):1920-8. PubMed ID: 21647730
    [Abstract] [Full Text] [Related]

  • 9. Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis.
    Bargiela D, Bianchi MT, Westover MB, Chibnik LB, Healy BC, De Jager PL, Xia Z.
    Neurology; 2017 Feb 14; 88(7):677-684. PubMed ID: 28087821
    [Abstract] [Full Text] [Related]

  • 10. Natalizumab for relapsing remitting multiple sclerosis.
    Pucci E, Giuliani G, Solari A, Simi S, Minozzi S, Di Pietrantonj C, Galea I.
    Cochrane Database Syst Rev; 2011 Oct 05; (10):CD007621. PubMed ID: 21975773
    [Abstract] [Full Text] [Related]

  • 11. Assessing understanding of individual risk and symptoms of progressive multifocal leukoencephalopathy in patients prescribed natalizumab for multiple sclerosis.
    Rath L, Vijiaratnam N, Skibina O.
    Intern Med J; 2017 Feb 05; 47(2):194-199. PubMed ID: 27862809
    [Abstract] [Full Text] [Related]

  • 12. Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
    Muñoz-Culla M, Irizar H, Castillo-Triviño T, Sáenz-Cuesta M, Sepúlveda L, Lopetegi I, López de Munain A, Olascoaga J, Baranzini SE, Otaegui D.
    Mult Scler; 2014 Dec 05; 20(14):1851-9. PubMed ID: 24852919
    [Abstract] [Full Text] [Related]

  • 13. Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
    Maillart E, Louapre C, Lubetzki C, Papeix C.
    Mult Scler; 2014 Apr 05; 20(4):505-9. PubMed ID: 24367037
    [Abstract] [Full Text] [Related]

  • 14. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.
    Ho PR, Koendgen H, Campbell N, Haddock B, Richman S, Chang I.
    Lancet Neurol; 2017 Nov 05; 16(11):925-933. PubMed ID: 28969984
    [Abstract] [Full Text] [Related]

  • 15. Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis.
    Dorsey ER, Thompson JP, Noyes K, Dick AW, Holloway RG, Schwid SR.
    Neurology; 2007 May 01; 68(18):1524-8. PubMed ID: 17470756
    [Abstract] [Full Text] [Related]

  • 16. Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab.
    Ziemssen T, Gass A, Wuerfel J, Bayas A, Tackenberg B, Limmroth V, Linker R, Mäurer M, Haas J, Stangel M, Meergans M, Harlin O, Hartung HP.
    BMC Neurol; 2016 Jul 12; 16():98. PubMed ID: 27405225
    [Abstract] [Full Text] [Related]

  • 17. Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations.
    van Kempen ZL, Leurs CE, Vennegoor A, Wattjes MP, Rispens T, Uitdehaag BM, Killestein J.
    Mult Scler; 2017 Jun 12; 23(7):995-999. PubMed ID: 28112019
    [Abstract] [Full Text] [Related]

  • 18. Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis.
    Clerico M, Artusi CA, Di Liberto A, Rolla S, Bardina V, Barbero P, De Mercanti SF, Durelli L.
    Expert Opin Drug Saf; 2017 Aug 12; 16(8):963-972. PubMed ID: 28641055
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.
    Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J, Curfman B, Miszkiel K, Mueller-Lenke N, Sanchez E, Barkhof F, Radue EW, Jäger HR, Clifford DB.
    N Engl J Med; 2006 Mar 02; 354(9):924-33. PubMed ID: 16510746
    [Abstract] [Full Text] [Related]

  • 20. Benefit of additional screening for progressive multifocal leukoencephalopathy in patients with multiple sclerosis taking natalizumab: a decision analysis.
    Landy DC, Hecht EM.
    Clin Neuropharmacol; 2014 Mar 02; 37(2):45-51. PubMed ID: 24614671
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.